Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension - The J-RHYTHM II study design for the investigation of upstream therapy for atrial fibrillation

Takeshi Yamashita, Satoshi Ogawa, Yoshifusa Aizawa, Hirotsugu Atarashi, Hiroshi Inoue, Tohru Ohe, Ken Okumura, Hiroshi Ohtsu, Takao Kato, Shiro Kamakura, Koichiro Kumagai, Yoshihisa Kurachi, Itsuo Kodama, Yukihiro Koretsune, Tetsunori Saikawa, Masayuki Sakurai, Kaoru Sugi, Haruaki Nakaya, Makoto Hirai, Atsushi HirayamaMasahiko Fukatani, Hideo Mitamura, Tsutomu Yamazaki, Eiichi Watanabe

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Mega trials of rhythm vs rate control could not demonstrate the usefulness of available antiarrhythmic drugs, so a more effective and safer therapy for atrial fibrillation (AF) is now required. One candidate is the so-called "upstream therapy", which refers to the blockade of upstream modifying elements (renin-angiotensin system, cathecholamines, oxidative stress etc) that contribute to the arrhythmogenic substrate. Methods and Results: The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension. To test the usefulness of this therapy, this study will reveal the recurrence rate of asymptomatic as well as symptomatic PAF during 1-year of treatment with candesartan or amlodipine, using daily transtelephonic monitoring. Conclusions: The J-RHYTHM II study will follow 400 patients with PAF and hypertension who were treated at approximately 50 sites throughout Japan, and will provide clinically important information.

Original languageEnglish
Pages (from-to)1318-1321
Number of pages4
JournalCirculation Journal
Volume70
Issue number10
DOIs
Publication statusPublished - 02-10-2006

Fingerprint

Angiotensin II Type 1 Receptor Blockers
Atrial Fibrillation
Hypertension
Calcium
Amlodipine
Therapeutics
Anti-Arrhythmia Agents
Renin-Angiotensin System
Angiotensin II
Japan
Oxidative Stress
Recurrence

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Yamashita, Takeshi ; Ogawa, Satoshi ; Aizawa, Yoshifusa ; Atarashi, Hirotsugu ; Inoue, Hiroshi ; Ohe, Tohru ; Okumura, Ken ; Ohtsu, Hiroshi ; Kato, Takao ; Kamakura, Shiro ; Kumagai, Koichiro ; Kurachi, Yoshihisa ; Kodama, Itsuo ; Koretsune, Yukihiro ; Saikawa, Tetsunori ; Sakurai, Masayuki ; Sugi, Kaoru ; Nakaya, Haruaki ; Hirai, Makoto ; Hirayama, Atsushi ; Fukatani, Masahiko ; Mitamura, Hideo ; Yamazaki, Tsutomu ; Watanabe, Eiichi. / Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension - The J-RHYTHM II study design for the investigation of upstream therapy for atrial fibrillation. In: Circulation Journal. 2006 ; Vol. 70, No. 10. pp. 1318-1321.
@article{00450d24e9ed4b0c8e33f0ddf4c503f5,
title = "Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension - The J-RHYTHM II study design for the investigation of upstream therapy for atrial fibrillation",
abstract = "Background: Mega trials of rhythm vs rate control could not demonstrate the usefulness of available antiarrhythmic drugs, so a more effective and safer therapy for atrial fibrillation (AF) is now required. One candidate is the so-called {"}upstream therapy{"}, which refers to the blockade of upstream modifying elements (renin-angiotensin system, cathecholamines, oxidative stress etc) that contribute to the arrhythmogenic substrate. Methods and Results: The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension. To test the usefulness of this therapy, this study will reveal the recurrence rate of asymptomatic as well as symptomatic PAF during 1-year of treatment with candesartan or amlodipine, using daily transtelephonic monitoring. Conclusions: The J-RHYTHM II study will follow 400 patients with PAF and hypertension who were treated at approximately 50 sites throughout Japan, and will provide clinically important information.",
author = "Takeshi Yamashita and Satoshi Ogawa and Yoshifusa Aizawa and Hirotsugu Atarashi and Hiroshi Inoue and Tohru Ohe and Ken Okumura and Hiroshi Ohtsu and Takao Kato and Shiro Kamakura and Koichiro Kumagai and Yoshihisa Kurachi and Itsuo Kodama and Yukihiro Koretsune and Tetsunori Saikawa and Masayuki Sakurai and Kaoru Sugi and Haruaki Nakaya and Makoto Hirai and Atsushi Hirayama and Masahiko Fukatani and Hideo Mitamura and Tsutomu Yamazaki and Eiichi Watanabe",
year = "2006",
month = "10",
day = "2",
doi = "10.1253/circj.70.1318",
language = "English",
volume = "70",
pages = "1318--1321",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "10",

}

Yamashita, T, Ogawa, S, Aizawa, Y, Atarashi, H, Inoue, H, Ohe, T, Okumura, K, Ohtsu, H, Kato, T, Kamakura, S, Kumagai, K, Kurachi, Y, Kodama, I, Koretsune, Y, Saikawa, T, Sakurai, M, Sugi, K, Nakaya, H, Hirai, M, Hirayama, A, Fukatani, M, Mitamura, H, Yamazaki, T & Watanabe, E 2006, 'Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension - The J-RHYTHM II study design for the investigation of upstream therapy for atrial fibrillation', Circulation Journal, vol. 70, no. 10, pp. 1318-1321. https://doi.org/10.1253/circj.70.1318

Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension - The J-RHYTHM II study design for the investigation of upstream therapy for atrial fibrillation. / Yamashita, Takeshi; Ogawa, Satoshi; Aizawa, Yoshifusa; Atarashi, Hirotsugu; Inoue, Hiroshi; Ohe, Tohru; Okumura, Ken; Ohtsu, Hiroshi; Kato, Takao; Kamakura, Shiro; Kumagai, Koichiro; Kurachi, Yoshihisa; Kodama, Itsuo; Koretsune, Yukihiro; Saikawa, Tetsunori; Sakurai, Masayuki; Sugi, Kaoru; Nakaya, Haruaki; Hirai, Makoto; Hirayama, Atsushi; Fukatani, Masahiko; Mitamura, Hideo; Yamazaki, Tsutomu; Watanabe, Eiichi.

In: Circulation Journal, Vol. 70, No. 10, 02.10.2006, p. 1318-1321.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension - The J-RHYTHM II study design for the investigation of upstream therapy for atrial fibrillation

AU - Yamashita, Takeshi

AU - Ogawa, Satoshi

AU - Aizawa, Yoshifusa

AU - Atarashi, Hirotsugu

AU - Inoue, Hiroshi

AU - Ohe, Tohru

AU - Okumura, Ken

AU - Ohtsu, Hiroshi

AU - Kato, Takao

AU - Kamakura, Shiro

AU - Kumagai, Koichiro

AU - Kurachi, Yoshihisa

AU - Kodama, Itsuo

AU - Koretsune, Yukihiro

AU - Saikawa, Tetsunori

AU - Sakurai, Masayuki

AU - Sugi, Kaoru

AU - Nakaya, Haruaki

AU - Hirai, Makoto

AU - Hirayama, Atsushi

AU - Fukatani, Masahiko

AU - Mitamura, Hideo

AU - Yamazaki, Tsutomu

AU - Watanabe, Eiichi

PY - 2006/10/2

Y1 - 2006/10/2

N2 - Background: Mega trials of rhythm vs rate control could not demonstrate the usefulness of available antiarrhythmic drugs, so a more effective and safer therapy for atrial fibrillation (AF) is now required. One candidate is the so-called "upstream therapy", which refers to the blockade of upstream modifying elements (renin-angiotensin system, cathecholamines, oxidative stress etc) that contribute to the arrhythmogenic substrate. Methods and Results: The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension. To test the usefulness of this therapy, this study will reveal the recurrence rate of asymptomatic as well as symptomatic PAF during 1-year of treatment with candesartan or amlodipine, using daily transtelephonic monitoring. Conclusions: The J-RHYTHM II study will follow 400 patients with PAF and hypertension who were treated at approximately 50 sites throughout Japan, and will provide clinically important information.

AB - Background: Mega trials of rhythm vs rate control could not demonstrate the usefulness of available antiarrhythmic drugs, so a more effective and safer therapy for atrial fibrillation (AF) is now required. One candidate is the so-called "upstream therapy", which refers to the blockade of upstream modifying elements (renin-angiotensin system, cathecholamines, oxidative stress etc) that contribute to the arrhythmogenic substrate. Methods and Results: The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension. To test the usefulness of this therapy, this study will reveal the recurrence rate of asymptomatic as well as symptomatic PAF during 1-year of treatment with candesartan or amlodipine, using daily transtelephonic monitoring. Conclusions: The J-RHYTHM II study will follow 400 patients with PAF and hypertension who were treated at approximately 50 sites throughout Japan, and will provide clinically important information.

UR - http://www.scopus.com/inward/record.url?scp=33749034218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749034218&partnerID=8YFLogxK

U2 - 10.1253/circj.70.1318

DO - 10.1253/circj.70.1318

M3 - Article

C2 - 16998266

AN - SCOPUS:33749034218

VL - 70

SP - 1318

EP - 1321

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 10

ER -